Pathogenesis of polycythaemia vera

Blood Reviews

Volumn 11, Issue 4, 1997, Pages 224-232

  Hinshelwood, S ^a   Bench, A J ^a   Green, A R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR;

CHROMOSOME 20; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; HUMAN; HUMAN CELL; KARYOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TRISOMY 8; X CHROMOSOME INACTIVATION;

EID: 0031469322     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90021-7     Document Type: Article

References (76)

1. Rosenthal N, Bassen FA. Course of polycythemia. Arch Intern Med 1938; 62: 903-917.
2. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
3. Pearson TC, Messinezy M. The diagnostic criteria of Polycythaemia Rubra Vera. Leukemia and Lymphoma 1996; 22: 87-93.
4. Kay HEM, Lawler SD, Millard RE. The chromosomes in polycythaemia vera. Br J Haematol 1966; 12: 507-528.
5. Lawler SD, Millard RE, Kay HEM. Further cytogenetical investigations in polycythaemia vera. Eur J Cancer 1970; 6: 223-233.
6. Rege-Cambrin G, Mecucci C, Tricot G et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987; 25: 233-245.
7. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia 1991; 5: 214-220.
8. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988; 72: 386-395.
9. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991; 66: 287-299.
10. Testa JR. Cytogenetic patterns in Polycythemia Vera. Cancer Genet Cytogenet 1980; 1: 207-215.
11. Busque L, Gilliland DG. Clonal evolution in acute myeloid leukemia. Blood 1993; 80: 337-342.
12. Gale RE, Wainscot JS. Clonal analysis using X-linked DNA polymorphisms. Br J Haematol 1993; 85: 2-8.
13. Busque L, Zhu J, DeHart D et al. An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. Nucleic Acids Res 1994; 22: 697-698.
14. Prchal JT, Prchal JF, Barany F, Guan YL. Transcriptional analysis of the active X chromosome in normal and clonal hematopoiesis. Blood 1993; 81: 269-271.
15. Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science 1965; 150: 67-69.
16. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinman L. Polycythemia vera; stem cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
17. Prchal J, Adamson JW Murphy S, Steinmann L, Fialkow PJ. The in vitro response of normal and abnormal stem cell lines to erythropoietin. J Clin Invest 1978; 61: 1044-1047.
18. Anger B, Janssen JWG, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 1990; 4: 258-261.
19. Lucas GS, Padua RA, Masters GS, Oscier DG, Jacobs A. The application of X chromosome gene probes to the diagnosis of myeloproliferative disease. Br J Haematol 1989; 72: 530-533.
20. Tan SS, Williams EA, Tarm PPL. X chromosome inactivation occurs at different times in different tissues of the post-implantation mouse embryo. Nat Genet 1993; 3: 170-174.
21. Gale RE, Wheadon H, Boulos P, Linch DC. Tissue specificity of X chromosome inactivation patterns. Blood 1994; 83: 2899-2905.
22. Raskind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest 1985; 75: 1388-1390.
23. El-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythaemia: advantages of studying T lymphocytes and platelets. Blood 1997; 89: 128-134.
24. Asimakopoulos FA, Gilbert JGR, Aldred MA, Pearson TC. Green AR. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood 1996; 88: 2690-2698.
25. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991; 88: 6848-6852.
26. Champion KM, Gilbert JGR, Asimakopoulos FA, Hinshelwood S, Green AR. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 1997; 97: 920-926.
27. Fey MF, Liechti-Gallati S, von Rohr A et al. Clonality and X inactivation patterns in haematopoietic cell populations detected by the highly informative M27β DNA probe. Blood 1994; 83: 931-938.
28. Busque L, Mio R, Mattioli J et al. Nonrandom X inactivation patterns in normal females: Lyonization ratios vary with age. Blood 1996; 88: 59-65.
29. Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 1997; 98: 512-519.
30. Prchal JF, Axelrad AA. Bone marrow responses in polycythemia vera. N Engl J Med 1974; 290: 1382.
31. Adamson JW, Singer JW, Catalano P et al. Further in vitro studies of hematopoietic regulation. J Clin Invest 1980; 66: 1363-1368.
32. Reid C. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Reviews 1987; 1: 133-140.
33. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982-1991.
34. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52: 1196-1199.
35. Migliaccio G, Migliaccio AR. Cloning of human erythroid progenitors (BFU-E) in the absence of fetal bovine serum. Br J Haematol 1987; 67: 129-133.
36. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC. Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin-3 and alpha interferon. Br J Haematol 1990; 75: 188-194.
37. Dai CH, Krantz SB, Dessypris EN, Means RT, Horn ST, Gilbert HS. Polycythemia vera II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80: 891-899.
38. Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythaemia vera III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994; 86: 12-21.
39. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro studies in an improved serum-free medium. Blood 1994; 83: 99-112.
40. de Wolf J, Hendriks D, Esselink M, Halie M, Vellenga E. The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythaemia vera. Br J Haematol 1994; 88: 242-246.
41. Kobayashi S, Teramura M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 1993; 83: 539-544.
42. Li Y, Hetet G, Maurer A-M, Chait Y, Dhermy D, Briere J. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol 1994; 87: 471-476.
43. Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythaemia vera and stimulates erythroid burst formation in vitro. Blood 1997; 89: 1862-1869.
44. Cassel A, Braester A, Quitt M, Froom P, Aghai E. Soluble factors from peripheral blood T-cells of patients with polycythaemia vera stimulate normal BFU-E. Leukemia 1993; 7: 1370-1373.
45. Shabbad E, Cassel A, Froom P, Aghai E. Effect of adherent cells on the regulation of BFU-E in patients with myeloproliferative disease. Am J Hematol 1990; 33: 225-229.
46. De La Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA 1993; 90: 4495-4499.
47. Sokol L, Prchal JF, Rado TA, Prchal JT. Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. Experimental Haematology 1994; 22: 447-453.
48. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995; 86: 15-22.
49. Le Couedic J-P, Mitjavila M-T, Villeval J-L et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 1996; 87: 1502-1511.
50. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994; 88: 794-802.
51. Chiba S. Takahashi T, Takeshita K et al. Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia. Blood 1997; 90: 97-104.
52. Haber D, Harlow E. Tumour suppressor genes: evolving definitions in the genomic age. Nat Genet 1997; 16: 320-322.
53. Westwood NB, Copson ER, Page LA, Miresluis AR, Brown KA, Pearson TC. Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythemia. J Clin Pathol 1995; 48: 525-530.
54. Kingmuller U, Lonerz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80: 729-738.
55. Asimakopoulos FA, Hinshelwood S, Gilbert JGR et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene 1997; 14: 1215-1222.
56. Dai CH, Krantz SB. Vanadate mimics the effect of stem cell factor on highly purified human burst-forming units-erythroid in vitro but not the effect of erythropoietin. Experimental Haematology 1992; 20: 1055.
57. Dai CH, Krantz SB, Sawyer ST. Polycythemia V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood 1997; 89: 3574.
58. Sui X, Krantz SB, Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood 1997; 90: 651-657.
59. Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth-factor-I receptor-beta subunit in circulating mononuclear cells of patients with polycythemia-vera. Blood 1995; 86: 877-882.
60. Moliterno A, Hankins WD, Spivak JL. Thrombopoietin fails to stimulate protein-tyrosine phosphorylation in polycythemia-vera platelets. Blood 1996; 88: 640a.
61. Wickrema A, Chen F, Barsotti C, Mavillo F. The homeobox (Hox) B9 gene is expressed in highly purified normal erythroid progenitors but not in polycythemia-vera (PV) cells. Blood 1996; 88: 639a.
62. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 1996; 95: 219-226.
63. Dewald GW, Schad CR, Lilla VC, Jalal SM. Frequency and photographs of Hgm 11 chromosome anomalies in bone-marrow samples from 3,996 patients with malignant hematologic neoplasms. Cancer Genet Cytogenet 1993; 68: 60-69.
64. Roulston D, Espinosa III R, Stoffel M, Bell GI, Le Beau MM. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 1993; 82: 3424-3429.
65. Asimakopoulos FA, White NJ, Nacheva E, Green AR. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodyslastic syndromes. Blood 1994; 84: 3086-3094.
66. Stoffel M, Le Beau MM, Espinosa R et al. A yeast artificial chromosome-based map of the region of chromosome 20 containing the diabetes-susceptibility gene, MODY1, and a myeloid leukaemia related gene. Proc Natl Acad Sci USA 1996; 93: 3937-3941.
67. Bench AJ, Aldred MA, Humphray SJ et al. Construction of a detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and its utilisation for deletion mapping. Manuscript submitted.
68. Asimakopoulos FA, Holloway TL, Nacheva EP, Scott MA, Fenaux P, Green AR. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood 1996; 87: 1561-1570.
69. Kralovics R, Guan Y, Prchal JT. Differences in gene-expression between normal and polycythemia vera CD34 cells. Blood 1995; 86: 733a.
70. Nunez C, Bostock V, Weaver D, Lucas GS, Brady G. Molecular dissection of myeloproliferative (MPS) and myelodysplastic (MDS) syndromes. Blood 1994; 85: 635a.
71. Kralovics R, Sokol L, Prchal JT. Identification of putative molecular lesion of polycythemia vera phenotype. Blood 1995; 86: 270a.
72. Rege-Cambrin G, Mecucci C, Tricot G et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987; 25: 233-245.
73. Taylor KM, Shetha M, Talpaz M et al. Myeloproliferative disorders: usefulness of X-linked probes in diagnosis. Leukemia 1989; 3: 419-422.
74. Kreipe H, Jaquet K, Felgner J, Radzun H-J, Parwaresch MR. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991; 78: 1814-1817.
75. Tsukamoto N, Morita K, Maehara T et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994; 86: 253-258.
76. Gregg XT, Liu Y, Prchal JT, Gartland GL, Prchal JF. Clonality in the myeloproliferative disorders. Blood 1997; 88: 1905.